Compare ResMed Inc. (RMD) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Simon Property Group Inc — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Simon Property Group Inc trades at $199.42 (market cap $64.59B). The key difference: Simon Property Group Inc is far larger — about 2× ResMed Inc.'s market cap, and Simon Property Group Inc pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Simon Property Group Inc for 99 Days on average.
| RMD | SPG | |
|---|---|---|
Market Cap | $31.89B | $64.59B |
Volume | 618,314 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $275.96 | $236.70 |
52-Week Low | $182.82 | $173.35 |
Typical Hold Time | 51 Days | 99 Days |
Enterprise Value | $31.24B | $93.03B |
Dividend Yield | 1.16% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
SPG trades at $199.61, up 1.02% today, amid a bearish technical signal with support at $198 and resistance at $201. The company reported strong 2025 results with net income of $4.63B and a net margin of 72.7%, though Q2 2026 EPS missed expectations. Recent news highlights strong leasing demand and the launch of Simon Media Network to monetize mall traffic.
Outlook is mixed: analyst consensus is a Buy with a $221.27 target, but technicals are bearish. Investment opportunity lies in solid fundamentals and a 4%+ dividend yield, while risks include rising bond yields, high debt levels, and potential redemption of preferred shares.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
